Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
With
Ono Pharmaceutical Co., Ltd.
Age
50–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
A diagnosis of dementia of the Alzheimer's type according to the DSM-IV criteria
A clinical diagnosis of probable AD according to NINCDS/ADRDA criteria
An MMSE score of ≥ 10 and ≤ 20 at baseline
You may not be if
Any medical or neurological conditions other than AD that could explain the patient's dementia
A current diagnosis of probable or possible vascular dementia
A score of \> 5 on the Modified Hachinski Ischemic Scale (MHIS)
A current DSM-IV Axis 1 diagnosis that may interfere with the evaluation of the patient's response to study medication.
Treated with donepezil or galantamine within last 4 weeks before the efficacy assessment at baseline.
an advanced severe progressive or unstable disease of any type that may interfere with efficacy and safety assessments or put the patient's at special risk
